AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) fell 2.8% on Tuesday . The company traded as low as $13.15 and last traded at $14.45. 978,000 shares were traded during mid-day trading, a decline of 13% from the average session volume of 1,125,797 shares. The stock had previously closed at $14.05.

A number of brokerages have weighed in on AMAG. Zacks Investment Research raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Morgan Stanley lowered their price objective on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Janney Montgomery Scott reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. Finally, Piper Jaffray Companies began coverage on AMAG Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $24.00.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.

Several large investors have recently made changes to their positions in AMAG. BlackRock Inc. boosted its stake in shares of AMAG Pharmaceuticals by 67,790.9% during the 1st quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after acquiring an additional 4,988,054 shares in the last quarter. State Street Corp lifted its stake in AMAG Pharmaceuticals by 75.2% in the 1st quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock valued at $56,876,000 after buying an additional 1,082,366 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in AMAG Pharmaceuticals by 152.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock valued at $23,129,000 after buying an additional 619,370 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in AMAG Pharmaceuticals by 175.1% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 525,989 shares of the specialty pharmaceutical company’s stock valued at $9,679,000 after buying an additional 334,811 shares in the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at approximately $3,958,000.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/16/amag-pharmaceuticals-inc-amag-trading-down-2-8.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.